Insulet (NASDAQ:PODD) Raised to Strong-Buy at BidaskClub

Share on StockTwits

BidaskClub upgraded shares of Insulet (NASDAQ:PODD) from a buy rating to a strong-buy rating in a research report report published on Saturday morning, BidAskClub reports.

A number of other analysts have also recently weighed in on the company. BTIG Research raised their price objective on Paypal from $114.00 to $130.00 and gave the stock a buy rating in a research report on Monday, May 6th. They noted that the move was a valuation call. Canaccord Genuity lowered their price objective on Jamieson Wellness from C$23.00 to C$20.00 in a research report on Monday, May 6th. JPMorgan Chase & Co. cut Sogou from a neutral rating to an underweight rating and lowered their price objective for the stock from $5.50 to $4.12 in a research report on Thursday, June 27th. Northland Securities reissued a buy rating and issued a $6.00 price objective on shares of EMCORE in a research report on Monday, June 10th. Finally, ValuEngine cut Virtu Financial from a hold rating to a sell rating in a research report on Tuesday, June 18th. Five investment analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $110.09.

Shares of NASDAQ PODD opened at $120.70 on Friday. The company has a debt-to-equity ratio of 2.68, a current ratio of 4.36 and a quick ratio of 3.71. The company has a market cap of $7.18 billion, a PE ratio of 2,414.00 and a beta of 1.12. The firm’s fifty day moving average is $116.09. Insulet has a 12-month low of $70.80 and a 12-month high of $124.38.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $0.07 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.02 by $0.05. The firm had revenue of $159.56 million during the quarter, compared to analysts’ expectations of $154.66 million. Insulet had a return on equity of 7.01% and a net margin of 2.37%. The business’s quarterly revenue was up 29.1% on a year-over-year basis. During the same quarter last year, the firm earned ($0.11) EPS. As a group, analysts forecast that Insulet will post 0.27 EPS for the current year.

In other Insulet news, COO Charles Alpuche sold 3,900 shares of Insulet stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $104.78, for a total transaction of $408,642.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Shacey Petrovic sold 895 shares of Insulet stock in a transaction dated Wednesday, June 5th. The stock was sold at an average price of $113.00, for a total value of $101,135.00. Following the sale, the insider now directly owns 95,559 shares of the company’s stock, valued at approximately $10,798,167. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 41,894 shares of company stock valued at $4,524,025. 3.50% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently modified their holdings of PODD. Manchester Capital Management LLC acquired a new stake in Insulet during the 1st quarter worth about $31,000. Meridian Wealth Management LLC purchased a new position in shares of Insulet during the 1st quarter valued at about $48,000. Quadrant Capital Group LLC raised its stake in shares of Insulet by 1,037.7% during the 1st quarter. Quadrant Capital Group LLC now owns 603 shares of the medical instruments supplier’s stock valued at $55,000 after buying an additional 550 shares during the last quarter. Flagship Harbor Advisors LLC raised its stake in shares of Insulet by 384.0% during the 1st quarter. Flagship Harbor Advisors LLC now owns 1,452 shares of the medical instruments supplier’s stock valued at $138,000 after buying an additional 1,152 shares during the last quarter. Finally, Nordea Investment Management AB purchased a new position in shares of Insulet during the 4th quarter valued at about $159,000.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.

Featured Story: Limitations to arbitrage trading

Analyst Recommendations for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

BABB  Price Reaches $0.0001 on Exchanges
BABB Price Reaches $0.0001 on Exchanges
Eterbase Tops 1-Day Volume of $392,818.00
Eterbase Tops 1-Day Volume of $392,818.00
Analyzing Dime Community Bancshares  and First Guaranty Bancshares
Analyzing Dime Community Bancshares and First Guaranty Bancshares
Brokerages Expect Flexion Therapeutics Inc  to Post -$0.98 EPS
Brokerages Expect Flexion Therapeutics Inc to Post -$0.98 EPS
Jesus Coin Price Tops $0.0000 on Major Exchanges
Jesus Coin Price Tops $0.0000 on Major Exchanges
ShowHand  Trading Down 54.4% This Week
ShowHand Trading Down 54.4% This Week


 
© 2006-2019 Zolmax.